



Minimal Disease Activity (MDA) Scale

The minimal disease activity index is a tool for measuring disease state in psoriatic arthritis.

The minimal disease activity index is a tool for measuring disease state in psoriatic arthritis. It is a composite index comprising seven domains: tender joint count, swollen joint count, psoriasis activity or extent, a functional index (HAQ), enthesitis and two patient completed visual analogue scores, one for pain and one for global disease activity. If 5 of the 7 criteria are met then the patient is deemed to be in minimal disease activity, if all 7 are met the patient is in a very low disease activity state. Almost all new pharmaceuticals tested for psoriatic arthritis are tested against this metric, in addition to others.

Commercial Licences:

If you are interested in using the MDA Scale for commercial purposes, including clinical, organisational, or consultancy applications, please get in touch to discuss licensing options. We offer licence agreements to suit different commercial needs.

Contact us at enquiries@licensing.leeds.ac.uk to begin the conversation about commercial licensing.

Academic/Research Licences (available to order):

The MDA Scale was originally developed in UK/English. It is available for academic and research purposes under the following terms:

- Original UK/English version: Free of charge for academic/research use only (i.e. strictly non-commercial purposes).
- Approval Process: All licence requests are subject to review and approval.
- Eligibility: Academic/research licences are only granted to individuals affiliated with a university or recognised research institution.
- Email Requirement: Requests **must** be submitted using an academic email address (either your own or your supervisor's).

References

Category

Healthcare Questionnaires &
Outcome Measures/Other Scales
Non-Software (HEBCI)

Authors

Philip Helliwell

View online page



1. Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, et al. ,
<https://www.jrheum.org/content/early/2019/02/12/jrheum.181089>
2. Fredricksson T, Pettersson U. , <https://pubmed.ncbi.nlm.nih.gov/357213/>
3. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. ,
<https://www.jrheum.org/content/38/5/898>
4. Fries JF, Spitz P, Kraines RG, Holman HR. ,
<https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780230202>
5. Healy P, Helliwell PS. , <https://pubmed.ncbi.nlm.nih.gov/18438903/>